◎ Sugi Atlas

Atlas / Drug / Pembrolizumab

Pembrolizumab

drug
On this page

Also known as KeytrudaLambrolizumabMK-3475PEMBROLIZUMAB COMPONENT OF KEYLYNK-010Pembrolizumab component of mk 7684aPembrolizumab component of mk-1308aSCH-900475

Summary

Pembrolizumab (CHEMBL3137343) is an approved antibody (ATC L01FF02) targeting PDCD1; indicated across 198 conditions including melanoma and non-small cell lung carcinoma; with CIViC clinical evidence for 48 variant-indication associations (e.g. TMB High in solid tumor).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Antibody
  • ATC class: L01FF02
  • Targets: 1 (PDCD1)
  • Indications: 198 conditions
  • Clinical trials: 2,241
  • Precision-oncology evidence (CIViC): 48 variant–indication associations

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL3137343
NamePembrolizumab
TypeAntibody
Max phase4
ATCL01FF02

Also known as: Keytruda, Lambrolizumab, MK-3475, Pembrolizumab, PEMBROLIZUMAB COMPONENT OF KEYLYNK-010, Pembrolizumab component of mk 7684a, Pembrolizumab component of mk-1308a, SCH-900475, PEMBROLIZUMAB

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
PDCD1programmed cell death 1 (CD279)Binding100%Q15116

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): PDCD1.

Top Reactome pathways

3 total, by targets touching each:

PathwayTargetsGenes
Co-inhibition by PD-11PDCD1
Potential therapeutics for SARS1PDCD1
PD-L1(CD274) glycosylation and translocation to plasma membrane1PDCD1

Dominant GO biological processes

GO termTargets
B cell apoptotic process1
adaptive immune response1
negative regulation of tolerance induction1
negative regulation of T cell mediated immune response to tumor cell1
negative regulation of B cell apoptotic process1
apoptotic process1
humoral immune response1
negative regulation of inflammatory response1
regulation of immune response1
negative regulation of immune response1
negative regulation of T cell receptor signaling pathway1
negative regulation of T cell activation1
positive regulation of T cell apoptotic process1
regulatory T cell apoptotic process1
immune system process1

Indications & clinical

Indications

55 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

IndicationPhaseMONDOEFO
melanoma4MONDO:0005105EFO:0000756
non-small cell lung carcinoma4MONDO:0005233EFO:0003060
metastatic melanoma4MONDO:0005191EFO:0002617
renal cell carcinoma4MONDO:0005086EFO:0000681
neoplasm4MONDO:0005070EFO:0000616
head and neck squamous cell carcinoma4MONDO:0010150EFO:0000181
Hodgkins lymphoma4MONDO:0004952EFO:0000183
squamous cell carcinoma4MONDO:0005096EFO:0000707
cutaneous melanoma4MONDO:0005012EFO:0000389
endometrium neoplasm4MONDO:0021251EFO:0004230
clear cell renal carcinoma4MONDO:0005005EFO:0000349
endometrial carcinoma4MONDO:0002447EFO:1001512
laryngeal squamous cell carcinoma4MONDO:0005595EFO:0006352
papillary renal cell carcinoma4MONDO:0017884EFO:0000640
squamous cell lung carcinoma4MONDO:0005097EFO:0000708
uterine corpus cancer4MONDO:0006003EFO:0007532
transitional cell carcinoma4MONDO:0006474EFO:1000601
renal carcinoma4MONDO:0005206EFO:0002890
collecting duct carcinoma4MONDO:0005220EFO:0003016
renal cell adenocarcinoma4MONDO:0005549EFO:0005708
hepatocellular carcinoma3MONDO:0007256EFO:0000182
gastric adenocarcinoma3MONDO:0005036EFO:0000503
mesothelioma3MONDO:0005065EFO:0000588
breast carcinoma3MONDO:0004989EFO:0000305
nasopharyngeal neoplasm3MONDO:0005375EFO:0004252
carcinoma of esophagus3MONDO:0019086EFO:0002916
carcinoma3MONDO:0004993EFO:0000313
small cell lung carcinoma3MONDO:0008433EFO:0000702
plasma cell myeloma3MONDO:0009693EFO:0001378
malignant pleural mesothelioma3MONDO:0005112EFO:0000770
cutaneous neuroendocrine carcinoma3MONDO:0019210EFO:1001471
metastatic prostate carcinoma3MONDO:0004956EFO:0000196
prostate adenocarcinoma3MONDO:0005082EFO:0000673
cervical carcinoma3MONDO:0005131EFO:0001061
breast neoplasm3MONDO:0021100EFO:0003869
biliary tract neoplasm3MONDO:0005304EFO:0003891
upper aerodigestive tract neoplasm3MONDO:0005398EFO:0004284
esophageal squamous cell carcinoma3MONDO:0005580EFO:0005922
head and neck cancer3MONDO:0005627EFO:0006859
colorectal carcinoma3MONDO:0024331EFO:1001951
colorectal adenocarcinoma3MONDO:0005008EFO:0000365
lung adenocarcinoma3MONDO:0005061EFO:0000571
gastric neoplasm3MONDO:0021085EFO:0003897
colorectal neoplasm3MONDO:0005335EFO:0004142
triple-negative breast carcinoma3MONDO:0005494EFO:0005537
urothelial carcinoma3MONDO:0040679EFO:0008528
urinary bladder neoplasm3MONDO:0004987EFO:0000294
cervical adenocarcinoma3MONDO:0005153EFO:0001416
brain cancer3MONDO:0001657MONDO:0001657
breast carcinoma in situ3MONDO:0004658MONDO:0004658
lung neoplasm3MONDO:0021117MONDO:0008903
head and neck neoplasm3MONDO:0005586EFO:0005950
brain neoplasm3MONDO:0021211EFO:0003833
lung carcinoma3MONDO:0005138EFO:0001071
prostate carcinoma3MONDO:0005159EFO:0001663

101 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)PhaseMONDOEFO
exocrine pancreatic carcinoma2MONDO:0005192EFO:0002618
ovarian neoplasm2MONDO:0021068EFO:0003893
neoplasm of mature B-cells2MONDO:0004949EFO:0000096
glioblastoma2MONDO:0018177EFO:0000519
acute myeloid leukemia2MONDO:0018874EFO:0000222
osteosarcoma2MONDO:0009807EFO:0000637
gliosarcoma2MONDO:0016681EFO:1001465
ovarian carcinoma2MONDO:0005140EFO:0001075
B-cell chronic lymphocytic leukemia2MONDO:0004948EFO:0000095
myelodysplastic syndrome2MONDO:0018881EFO:0000198
adenoid cystic carcinoma2MONDO:0004971EFO:0000231
diffuse large B-cell lymphoma2MONDO:0018905EFO:0000403
lymphoma2MONDO:0005062EFO:0000574
sarcoma2MONDO:0005089EFO:0000691
malignant peripheral nerve sheath tumor2MONDO:0017827EFO:0000760
tumor of meninges2MONDO:0016743EFO:0003851
oral cavity neoplasm2MONDO:0021245EFO:0003868
cholangiocarcinoma2MONDO:0019087EFO:0005221
non-Hodgkin lymphoma2MONDO:0018908EFO:0005952
male breast carcinoma2MONDO:0005628EFO:0006861
alveolar soft part sarcoma2MONDO:0011655EFO:0007143
thymic carcinoma2MONDO:0006451EFO:1000576
thymoma2MONDO:0006456EFO:1000581
rectal cancer2MONDO:0006519EFO:1000657
Sezary syndrome2MONDO:0017844EFO:1000785
inflammatory breast carcinoma2MONDO:0006804EFO:1000984
mycosis fungoides2MONDO:0009691EFO:1001051
neuroendocrine neoplasm2MONDO:0019496EFO:1001901
soft tissue sarcoma2MONDO:0018078EFO:1001968
Kaposi’s sarcoma2MONDO:0005055EFO:0000558
lymphoid neoplasm2MONDO:0005157EFO:0001642
pancreatic neoplasm2MONDO:0021040EFO:0003860
skin neoplasm2MONDO:0002531EFO:0004198
Waldenstrom macroglobulinemia2MONDO:0100280EFO:0009441
fallopian tube carcinoma2MONDO:0006206EFO:1000251
adrenal cortex carcinoma2MONDO:0006639EFO:1000796
oropharynx cancer2MONDO:0004608EFO:1001931
oral mucosa leukoplakia2MONDO:0004844HP:0002745
hereditary breast ovarian cancer syndrome2MONDO:0003582Orphanet:145
angiosarcoma2MONDO:0016982EFO:0003968
viral pneumonia2MONDO:0006012EFO:0007541
penile carcinoma2MONDO:0006360EFO:1000465
thyroid gland undifferentiated (anaplastic) carcinoma2MONDO:0006468EFO:1000595
mature T-cell and NK-cell non-Hodgkin lymphoma2MONDO:0000430MONDO:0000430
salivary gland cancer2MONDO:0004669MONDO:0000521
anus neoplasm2MONDO:0003046MONDO:0001879
peritoneal neoplasm2MONDO:0006901MONDO:0002087
neuroendocrine carcinoma2MONDO:0002120MONDO:0002120
fallopian tube neoplasm2MONDO:0021092MONDO:0002158
papilloma2MONDO:0002363MONDO:0002363
kidney cancer2MONDO:0002367MONDO:0002367
ovarian cancer2MONDO:0008170MONDO:0008170
follicular lymphoma2MONDO:0018906MONDO:0018906
nasal cavity and paranasal sinus lethal midline granuloma2MONDO:0006828MONDO:0019472
colonic neoplasm2MONDO:0005401MONDO:0021063
in situ carcinoma2MONDO:0004647MONDO:0024474
carcinoid tumor2MONDO:0005369MONDO:0024503
thyroid gland carcinoma2MONDO:0015075EFO:0002892
vulvar carcinoma2MONDO:0005215EFO:0002921
metastatic neoplasm2MONDO:0024883EFO:0009709
parotid gland cancer2MONDO:0004700MONDO:0004700
hematopoietic and lymphoid system neoplasm2MONDO:0002334MONDO:0044881
severe acute respiratory syndrome2MONDO:0005091MONDO:0100096
skin carcinoma2MONDO:0002656EFO:0009259
gallbladder neoplasm2MONDO:0021253MONDO:0005411
female reproductive system neoplasm2MONDO:0021148MONDO:0021148
adenocarcinoma2MONDO:0004970EFO:0000228
uterine carcinosarcoma2MONDO:0006485EFO:1000613
carcinosarcoma2MONDO:0002928MONDO:0002928
gastrointestinal stromal tumor2MONDO:0011719MONDO:0011719
meningioma2MONDO:0016642MONDO:0016642
vulva cancer2MONDO:0001528MONDO:0001528
peripheral T-cell lymphoma, not otherwise specified2MONDO:0004964EFO:0000211
thyroid gland follicular carcinoma2MONDO:0005034EFO:0000501
thyroid gland papillary carcinoma2MONDO:0005075EFO:0000641
kidney neoplasm2MONDO:0021163EFO:0003865
progressive multifocal leukoencephalopathy2MONDO:0016318EFO:0007455
malignant pancreatic neoplasm2MONDO:0009831EFO:1000359
paraganglioma2MONDO:0000448EFO:1000453
uveal melanoma2MONDO:0006486EFO:1000616
marginal zone lymphoma2MONDO:0017604EFO:1000630
pancreatic ductal adenocarcinoma2MONDO:0005184MONDO:0005184
nasopharyngeal carcinoma2MONDO:0015459MONDO:0015459
B-cell acute lymphoblastic leukemia1MONDO:0004947EFO:0000094
neuroblastoma1MONDO:0005072EFO:0000621
HIV infectious disease1MONDO:0005109EFO:0000764
primary cutaneous T-cell non-Hodgkin lymphoma1MONDO:0000607EFO:0002913
leukemia1MONDO:0005059EFO:0000565
mantle cell lymphoma1MONDO:0018876EFO:1001469
uterine cancer1MONDO:0002715MONDO:0002715
lymphoid leukemia1MONDO:0005402EFO:0004289
basal cell carcinoma1MONDO:0020804MONDO:0005341
glioma1MONDO:0021042MONDO:0100342
astrocytoma (excluding glioblastoma)1MONDO:0019781EFO:0000272
anaplastic astrocytoma1MONDO:0016684EFO:0002499
Ewing sarcoma1MONDO:0012817EFO:0000174
synovial sarcoma1MONDO:0010434EFO:0001376
human papilloma virus infection1MONDO:0005161EFO:0001668
rhabdomyosarcoma1MONDO:0005212EFO:0002918
bile duct carcinoma1MONDO:0005496EFO:0005540
undifferentiated pleomorphic sarcoma1MONDO:0002142EFO:1001972

40 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 2,241.

Phase distribution

PhaseTrials
PHASE21,009
PHASE1466
PHASE1/PHASE2366
PHASE3272
Not specified55
EARLY_PHASE136
PHASE2/PHASE328
PHASE49

Top trials by phase / activity

NCTPhaseStatusTitle
NCT05235737PHASE4RECRUITINGThe Assessment of Immune Response in Newly Diagnosed Glioblastoma Patients Treated With Pembrolizumab
NCT05689671PHASE4ACTIVE_NOT_RECRUITINGPemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma
NCT06031233PHASE4RECRUITINGEvaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie
NCT06764095PHASE4RECRUITINGEnfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial
NCT07010393PHASE4NOT_YET_RECRUITINGGenotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study
NCT03134456PHASE4COMPLETEDPembrolizumab for Metastatic NSCLC Patients Expressing PD-L1 Who Have Their Own PDX
NCT03715205PHASE4COMPLETEDStudy to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593)
NCT03891979PHASE4WITHDRAWNGut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma
NCT04489888PHASE4COMPLETEDA Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10)
NCT02362594PHASE3ACTIVE_NOT_RECRUITINGStudy of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)
NCT02506153PHASE3ACTIVE_NOT_RECRUITINGPhysician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
NCT02811861PHASE3ACTIVE_NOT_RECRUITINGLenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
NCT02954874PHASE3ACTIVE_NOT_RECRUITINGTesting MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
NCT03244384PHASE3ACTIVE_NOT_RECRUITINGTesting MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer
NCT03390504PHASE3ACTIVE_NOT_RECRUITINGA Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
NCT03425643PHASE3ACTIVE_NOT_RECRUITINGEfficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
NCT03486873PHASE3RECRUITINGLong-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
NCT03553836PHASE3ACTIVE_NOT_RECRUITINGSafety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
NCT03711032PHASE3ACTIVE_NOT_RECRUITINGEfficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
NCT03712605PHASE3ACTIVE_NOT_RECRUITINGTesting Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After Surgery, STAMP Trial
NCT03765918PHASE3ACTIVE_NOT_RECRUITINGStudy of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
NCT03768063PHASE3ACTIVE_NOT_RECRUITINGA Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
NCT03774732PHASE3ACTIVE_NOT_RECRUITINGPD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer
NCT03793179PHASE3ACTIVE_NOT_RECRUITINGTesting the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer
NCT03834493PHASE3ACTIVE_NOT_RECRUITINGStudy of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
NCT03914612PHASE3ACTIVE_NOT_RECRUITINGTesting the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
NCT03924895PHASE3ACTIVE_NOT_RECRUITINGPerioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
NCT04093167PHASE2/PHASE3RECRUITINGStudy of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer
NCT04194944PHASE3ACTIVE_NOT_RECRUITINGA Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
NCT04210115PHASE3ACTIVE_NOT_RECRUITINGStudy of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
NCT04214067PHASE3ACTIVE_NOT_RECRUITINGTesting the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer
NCT04223856PHASE3ACTIVE_NOT_RECRUITINGEnfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer
NCT04241185PHASE3ACTIVE_NOT_RECRUITINGEfficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
NCT04267848PHASE3RECRUITINGTesting the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
NCT04335669PHASE3ACTIVE_NOT_RECRUITINGNordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC
NCT04339218PHASE3RECRUITINGCryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung Adenocarcinoma
NCT04380636PHASE3ACTIVE_NOT_RECRUITINGStudy of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
NCT04534205PHASE2/PHASE3RECRUITINGA Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
NCT04547504PHASE3ACTIVE_NOT_RECRUITINGPEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %
NCT04613596PHASE2/PHASE3RECRUITINGPhase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
NCT04624204PHASE3ACTIVE_NOT_RECRUITINGPlacebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
NCT04634877PHASE3ACTIVE_NOT_RECRUITINGStudy of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
NCT04637594PHASE3ACTIVE_NOT_RECRUITINGTrying to Find the Correct Length of Treatment With Immune Checkpoint Therapy
NCT04657991PHASE3ACTIVE_NOT_RECRUITINGA Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
NCT04736706PHASE3ACTIVE_NOT_RECRUITINGA Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
NCT04747054PHASE3RECRUITINGStudy on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers
NCT04807673PHASE3RECRUITINGPembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)
NCT04895358PHASE3ACTIVE_NOT_RECRUITINGStudy of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
NCT04949256PHASE3ACTIVE_NOT_RECRUITINGEfficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)
NCT05048797PHASE3ACTIVE_NOT_RECRUITINGA Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
NCT05055908PHASE3RECRUITINGEfficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors
NCT05077215PHASE3NOT_YET_RECRUITINGEfficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer
NCT05085028PHASE3RECRUITINGA Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT05096663PHASE2/PHASE3ACTIVE_NOT_RECRUITINGTesting the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
NCT05116189PHASE3ACTIVE_NOT_RECRUITINGPembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
NCT05155254PHASE3ACTIVE_NOT_RECRUITINGIO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)
NCT05173987PHASE3ACTIVE_NOT_RECRUITINGStudy of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
NCT05215340PHASE3RECRUITINGStudy of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
NCT05224141PHASE3ACTIVE_NOT_RECRUITINGPembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
NCT05239728PHASE3ACTIVE_NOT_RECRUITINGA Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
NCT05239741PHASE3ACTIVE_NOT_RECRUITINGStudy of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)
NCT05298423PHASE3ACTIVE_NOT_RECRUITINGStudy of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)
NCT05317858PHASE3RECRUITINGBlood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
NCT05352672PHASE3ACTIVE_NOT_RECRUITINGClinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
NCT05382286PHASE3ACTIVE_NOT_RECRUITINGStudy of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05429697PHASE2/PHASE3RECRUITINGStudy of SMT-NK Inj. Plus Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract Cancer
NCT05499390PHASE3ACTIVE_NOT_RECRUITINGAK112 in Advanced Non-Small Cell Lung Cancer
NCT05502237PHASE3ACTIVE_NOT_RECRUITINGZimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
NCT05549037PHASE3RECRUITINGEffect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC
NCT05555732PHASE3ACTIVE_NOT_RECRUITINGDatopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
NCT05608291PHASE3ACTIVE_NOT_RECRUITINGA Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
NCT05609968PHASE3ACTIVE_NOT_RECRUITINGStudy of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
NCT05629585PHASE3ACTIVE_NOT_RECRUITINGA Study of Dato-DXd With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
NCT05633602PHASE3ACTIVE_NOT_RECRUITINGRamucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
NCT05633654PHASE3RECRUITINGStudy of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
NCT05668650PHASE3RECRUITINGDouble-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage IV NSCLC
NCT05687266PHASE3ACTIVE_NOT_RECRUITINGPhase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
NCT05721755PHASE3ACTIVE_NOT_RECRUITINGCombining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT05722015PHASE3ACTIVE_NOT_RECRUITINGA Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)
NCT05812807PHASE3RECRUITINGPembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
NCT05815927PHASE3RECRUITINGPembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer
NCT05899049PHASE3ACTIVE_NOT_RECRUITINGA Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study
NCT05899608PHASE3RECRUITINGClinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
NCT05911295PHASE3ACTIVE_NOT_RECRUITINGDisitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
NCT05920356PHASE3RECRUITINGA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
NCT05929768PHASE3RECRUITINGShorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
NCT05933577PHASE3ACTIVE_NOT_RECRUITINGA Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
NCT05984277PHASE3ACTIVE_NOT_RECRUITINGA Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
NCT05987332PHASE2/PHASE3ACTIVE_NOT_RECRUITINGIDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
NCT06077760PHASE3RECRUITINGA Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
NCT06081244PHASE3RECRUITINGNeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)
NCT06082167PHASE2/PHASE3ACTIVE_NOT_RECRUITINGStudy of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT06093425PHASE3NOT_YET_RECRUITINGCombination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma
NCT06096844PHASE3RECRUITINGChemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
NCT06102395PHASE3RECRUITINGEvaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC
NCT06103864PHASE3RECRUITINGA Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator’s Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
NCT06112379PHASE3ACTIVE_NOT_RECRUITINGA Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
NCT06119581PHASE3RECRUITINGA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06146777PHASE3NOT_YET_RECRUITINGMulti-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant Therapy
NCT06151574PHASE3ACTIVE_NOT_RECRUITINGBeamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Clinical evidence (CIViC)

Variant × indication × effect (48 predictive associations from 52 curated evidence items):

VariantIndicationEffectTherapyLevelCIViC
TMB HighSolid TumorSensitivity/ResponsePembrolizumabCIViC AEID12082 +2
ERBB2 AmplificationStomach CancerSensitivity/ResponsePembrolizumab + Trastuzumab + ChemotherapyCIViC AEID11251
ERBB2 AmplificationGastroesophageal Junction AdenocarcinomaSensitivity/ResponsePembrolizumab + Trastuzumab + ChemotherapyCIViC AEID11252
CD274 ExpressionLung Non-small Cell CarcinomaSensitivity/ResponsePembrolizumabCIViC BEID1733 +1
CD274 ExpressionMelanomaSensitivity/ResponseNivolumab + PembrolizumabCIViC BEID704 +1
CD274 ExpressionLung Non-small Cell CarcinomaSensitivity/ResponseAtezolizumab + Avelumab + Nivolumab + PembrolizumabCIViC BEID1167
CD274 ExpressionMerkel Cell CarcinomaSensitivity/ResponsePembrolizumabCIViC BEID1578
CD274 ExpressionLung Non-small Cell CarcinomaSensitivity/ResponseAtezolizumab + Avelumab + Pembrolizumab + Nivolumab + DurvalumabCIViC BEID4857
CD274 ExpressionLung Non-small Cell CarcinomaSensitivity/ResponsePembrolizumab + NivolumabCIViC BEID743
HLA-DRA EXPRESSIONSkin MelanomaSensitivity/ResponseNivolumab + Atezolizumab + PembrolizumabCIViC BEID985
MET Exon 14 Skipping Mutation AND CD274 OverexpressionLung Non-small Cell CarcinomaSensitivity/ResponsePembrolizumabCIViC BEID11419
MSI HighEndometrial CarcinomaSensitivity/ResponsePembrolizumabCIViC BEID12364
PBRM1 Loss-of-functionRenal Cell CarcinomaSensitivity/ResponseNivolumab + PembrolizumabCIViC BEID7536
PDCD1LG2 EXPRESSIONHead And Neck CancerSensitivity/ResponsePembrolizumabCIViC BEID5917
TMB HighLung Non-small Cell CarcinomaSensitivity/ResponsePembrolizumabCIViC BEID12083
TMB HighColorectal CancerSensitivity/ResponsePembrolizumabCIViC BEID12574
TP53 MutationCancerSensitivity/ResponseEprenetapopt + PembrolizumabCIViC BEID12033
B2M MutationColorectal CancerResistanceNivolumab + PembrolizumabCIViC BEID7271
DNMT3A MutationCancerResistanceAtezolizumab + Nivolumab + PembrolizumabCIViC BEID2926
PTEN MutationGlioblastomaResistanceNivolumab + PembrolizumabCIViC BEID8176
STK11 MutationLung AdenocarcinomaResistanceNivolumab + Atezolizumab + PembrolizumabCIViC BEID6441
MDM2 AmplificationCancerAdverse ResponseNivolumab + Pembrolizumab + IpilimumabCIViC BEID2916
MDM4 AmplificationCancerAdverse ResponseAtezolizumab + Nivolumab + PembrolizumabCIViC BEID2925
MDM4 EXPRESSIONCancerAdverse ResponseNivolumab + Atezolizumab + PembrolizumabCIViC BEID2917
DEK::AFF2 FusionHead And Neck CancerSensitivity/ResponsePembrolizumabCIViC CEID7304
KRAS G12VSolid Tumors, AdvancedSensitivity/ResponseMRNA Vaccine + PembrolizumabCIViC CEID12180
MET Exon 14 Skipping MutationLung AdenocarcinomaSensitivity/ResponsePembrolizumab + Carboplatin/Pemetrexed RegimenCIViC CEID11487
MET Exon 14 Skipping Mutation AND CD274 OverexpressionLung Sarcomatoid CarcinomaSensitivity/ResponseCarboplatin/Pemetrexed Regimen + PembrolizumabCIViC CEID11457
PAPPA2 Y1520XLung AdenocarcinomaSensitivity/ResponsePembrolizumabCIViC CEID4774
POLD1 C284YLung AdenocarcinomaSensitivity/ResponsePembrolizumabCIViC CEID4776

+18 more predictive associations (showing top 30 by level).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

4 molecules share ≥1 primary target. Top 4 by shared-target count:

MoleculeSourceStatusShared targets
PYRVINIUMChEMBLPhase 4 (approved)PDCD1
RIFABUTINChEMBLPhase 4 (approved)PDCD1
GefitinibPubChemApprovedPDCD1
PomalidomidePubChemApprovedPDCD1

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.4
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot